Cellectricon Receives Milestone Order for Cellaxess®HT High Throughput RNAi Screening System
News Nov 14, 2008
Cellectricon announces that it has received its most significant and largest single order to date. The order includes three Cellaxess®HT systems and the customer is a leading US biotech firm.
“An order of this magnitude proves the system’s unique features and value, and validates Cellectricon’s strategy to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations.” says Jonas Ohlsson, CEO at Cellectricon.
“Cellectricon has developed the Cellaxess®HT system in close collaboration with leading pharmaceutical companies and academic research groups to meet the rapidly growing demand for a true high throughput transfection screening technology, capable of reagent-free delivery of genetic material to biologically relevant cell types,” Ohlsson said.
Cellaxess®HT is claimed by the company to be the world’s first fully automated workstation for high throughput RNAi screening on biologically relevant cell types. The system is designed to enable reagent free delivery of siRNA and cDNA to a wide range of primary cells and cell lines with viability at a throughput of 50, 000 wells per day.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.